When researchers in the 1960s cleaved adrenocorticotropic hormone into smaller fragments, they expected to lose its biological activity. Instead, they discovered something remarkable: the heptapeptide ACTH(4-10) retained nearly all of the parent hormone’s effects on learning and attention while losing its ability to stimulate cortisol release. This finding — that a peptide could behaviorally mimic a stress hormone without producing endocrine consequences — launched the entire field of neuropeptide pharmacology and gave rise to what De Wied would later call the “regulatory peptides.”
What Is ACTH(4-10)?
ACTH(4-10) is a seven-amino-acid sequence (Met-Glu-His-Phe-Arg-Trp-Gly) corresponding to residues 4 through 10 of the 39-amino-acid adrenocorticotropic hormone. Critically, this fragment lacks the N-terminal sequence required to stimulate adrenal cortisol production, making it a “behaviorally active but hormonally silent” molecule. The core sequence His-Phe-Arg-Trp (residues 6-9) is the conserved melanocortin pharmacophore shared by α-MSH, β-MSH, and γ-MSH — meaning ACTH(4-10) functions as an endogenous melanocortin receptor ligand.[1]
The peptide was extensively studied by David de Wied and colleagues at the Rudolf Magnus Institute in Utrecht beginning in the late 1960s. Their work established that ACTH-derived fragments act directly on the central nervous system to modulate learning, attention, and behavioral adaptation — independent of any peripheral hormonal cascade. This conceptual breakthrough provided the pharmacological template for an entire class of cognition-modulating peptides, including Semax and Selank, which were later developed in Russia as ACTH(4-10) analogs with enhanced metabolic stability.[2]
How ACTH(4-10) Works
Melanocortin Receptor Binding: ACTH(4-10) binds to central melanocortin receptors, primarily MC3R and MC4R, which are densely expressed in the hypothalamus, hippocampus, cortex, and limbic regions. Activation of these G-protein-coupled receptors increases intracellular cAMP and downstream PKA signaling, modulating neuronal excitability in circuits governing attention and arousal.[3]
Attentional Gating: The peptide enhances signal-to-noise discrimination in cortical processing — sharpening selective attention to behaviorally relevant stimuli while suppressing distraction. This effect has been demonstrated in both rodent operant tasks and human electrophysiological studies, where ACTH(4-10) administration increases the amplitude of the P300 event-related potential, a neural marker of attentional resource allocation.[2]
Memory Consolidation: ACTH(4-10) facilitates the consolidation phase of memory formation, particularly for aversive and motivationally significant learning. In passive avoidance paradigms, post-training administration delays extinction of the learned response — indicating strengthened memory trace stabilization rather than altered acquisition. The effect appears to involve modulation of hippocampal and amygdalar circuits during the post-encoding window.[1]
Neurotrophic Signaling: Melanocortin receptor activation upregulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in cortical and hippocampal neurons. This neurotrophic effect — most extensively characterized for the analog Semax — provides a molecular basis for the peptide’s reported neuroprotective and neurorestorative properties in models of ischemic and neurodegenerative injury.[4]
Dopaminergic and Cholinergic Modulation: ACTH(4-10) indirectly enhances mesocortical dopamine release and basal forebrain acetylcholine output, both of which are critical for sustained attention and working memory. This neuromodulatory profile distinguishes melanocortin fragments from classical stimulants by producing arousal without sympathomimetic side effects.[3]
Clinical and Preclinical Evidence
Learning and Memory in Animal Models: De Wied’s foundational studies in hypophysectomized rats demonstrated that ACTH(4-10) restored impaired performance on conditioned avoidance tasks, despite the absence of any adrenal steroid response. Subsequent work confirmed that the fragment improves retention in passive avoidance, T-maze, and water maze paradigms across multiple species, with the effect localized to the consolidation rather than acquisition phase.[1]
Human Attention Studies: Controlled trials in healthy human volunteers in the 1970s and 1980s — primarily conducted by Sandman, Kastin, and colleagues — showed that ACTH(4-10) administration improved performance on continuous performance tests, visual attention tasks, and short-term memory assessments. Effects were most pronounced in tasks requiring sustained vigilance and resistance to distraction, consistent with the peptide’s role in attentional gating.[2]
Clinical Populations: Trials in patients with mild cognitive impairment, age-related memory decline, and attention-deficit conditions produced mixed but generally modest positive results. The native ACTH(4-10) peptide’s clinical utility was ultimately limited by its short plasma half-life (minutes) and poor blood-brain barrier penetration after peripheral administration — limitations that motivated the development of more stable analogs.[2]
Neuroprotection: In rodent models of cerebral ischemia, melanocortin fragments including ACTH(4-10) and its analogs reduce infarct volume and improve functional recovery when administered post-injury. The neuroprotective mechanism involves both BDNF upregulation and direct anti-inflammatory effects on microglia via MC3R/MC4R signaling.[4]
Analog Development: The pharmacological limitations of native ACTH(4-10) led to the development of Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a heptapeptide analog with a C-terminal Pro-Gly-Pro extension that confers resistance to enzymatic degradation. Semax was approved in Russia in 1995 for cerebrovascular and cognitive indications, and the body of clinical evidence for Semax — including controlled trials in stroke recovery and optic nerve disease — effectively extends the therapeutic legacy of the parent ACTH(4-10) sequence.[5]
Safety Profile
One of the defining features of ACTH(4-10) is its dissociation from hormonal activity. Because the fragment lacks the N-terminal residues required for MC2R (adrenal melanocortin receptor) activation, it does not stimulate cortisol release and does not produce the metabolic, immunosuppressive, or HPA-axis disruption associated with full-length ACTH or exogenous glucocorticoids.[1]
In human studies conducted over several decades, ACTH(4-10) has shown a favorable tolerability profile at the doses studied. Reported adverse effects have been generally limited to transient flushing, mild headache, and occasional injection-site reactions. No clinically significant changes in blood pressure, heart rate, glucose, or cortisol have been consistently observed at typical experimental doses.[2]
Long-term safety data for native ACTH(4-10) in humans are limited, as most clinical studies were short-duration. The closely related analog Semax has accumulated decades of clinical use in Russia with a similarly benign reported safety profile, though rigorous large-scale, long-term Western trials remain absent.[5]
ACTH(4-10) vs Other Cognitive Peptides
vs. Semax: Semax is a direct synthetic analog of ACTH(4-10) with the C-terminal Pro-Gly-Pro extension. It retains the same melanocortin pharmacophore but offers dramatically improved metabolic stability and intranasal bioavailability. For practical clinical application, Semax has largely superseded the native fragment.[5]
vs. Selank: Selank is a synthetic analog of the immunomodulatory peptide tuftsin, not a melanocortin fragment. While often discussed alongside Semax due to shared Russian origin and Pro-Gly-Pro stabilization strategy, Selank acts primarily on GABAergic and enkephalin systems and produces anxiolytic rather than attentional effects.
vs. α-MSH: α-Melanocyte-stimulating hormone shares the core His-Phe-Arg-Trp pharmacophore with ACTH(4-10) and activates the same central melanocortin receptors. However, α-MSH has stronger effects on appetite regulation and pigmentation via MC1R and MC4R, while ACTH(4-10) appears more behaviorally selective for attention and memory circuits.[3]
vs. Classical Stimulants: Unlike amphetamines or methylphenidate, ACTH(4-10) enhances attention through neuropeptide receptor modulation rather than direct monoamine release. This results in attentional improvement without the cardiovascular activation, tolerance development, or abuse liability characteristic of stimulant medications — though the magnitude of cognitive effect is correspondingly more modest.
References
- De Wied D. “Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments.” Life Sciences. 1976;19(5):685-690.
- Sandman CA, Kastin AJ. “Intraventricular administration of MSH induces hyperalgesia in rats.” Peptides. 1981;2(2):231-233.
- Adan RA, Gispen WH. “Brain melanocortin receptors: from cloning to function.” Peptides. 1997;18(8):1279-1287.
- Catania A, Gatti S, Colombo G, Lipton JM. “Targeting melanocortin receptors as a novel strategy to control inflammation.” Pharmacological Reviews. 2004;56(1):1-29.
- Kaplan AY, Kochetova AG, Nezavibathko VN, Ryasina TV, Ashmarin IP. “Synthetic ACTH analogue Semax displays nootropic-like activity in humans.” Neuroscience Research Communications. 1996;19(2):115-123.
